Fagron NV (FAGR) | Stock Overview & Key Data
Fagron NV | Large-cap | Healthcare
Fagron NV | Large-cap | Healthcare
Fagron NV Performance Comparison
Stock Range
Today's Range
Low: €19.24
High: €19.76
on September 18, 2025
52 Week Range
Low: €15.14
High: €23.50
on December 23, 2024
on July 31, 2025
All-Time High: €41.80 on August 4, 2014
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€1.5B
EPS
1.17
P/E Ratio (TTM)
17.08
Forward P/E
15.14
P/B Ratio
2.91
PEG Ratio
N/A
Div. Yield
1.60%
ROE
17.53%
Beta
0.240
Debt to Equity
80.02
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
15.38%
Profit Margin
9.33%
Returns and Earnings
Return on Assets (TTM)
8.06%
Return on Equity (TTM)
17.53%
EBITDA
€164.0M
Net Income (TTM)
€85.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€12.61
Quarterly Revenue Growth (YoY)
10.90%
Quarterly Earnings Growth (YoY)
12.70%
Dividend Information
Last 12-Month Dividend
€0.35
Current Dividend Yield
1.60%
3-Year Average Dividend Yield
1.58%
3-Year Average Annual Dividend
€0.30
3-Year Total Dividends
€0.90
Ex-Dividend Date
May 19, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Fagron NV FAGR | 1.46B Large-cap | -6.22% | -5.77% | -10.50% | 2.62% | 16.95% | 4.93% | 54.82% | -8.07% |
| Argenx SE ARGX | 39.22B Large-cap | -5.56% | 7.85% | 30.80% | 9.45% | 1.24% | 28.30% | 73.61% | 195.04% |
| UCB S.A UCB | 39.10B Large-cap | -3.00% | 4.12% | 31.16% | 11.75% | 6.35% | 25.08% | 193.06% | 108.12% |
| Ion Beam IBAB | 333.57M Mid-cap | -5.48% | -5.32% | -5.48% | -14.29% | -19.06% | -18.34% | -13.75% | 4.94% |
| Onward Medical N.V ONWD | 245.24M Mid-cap | 0.19% | 24.15% | 16.29% | 9.83% | -3.75% | 5.11% | -16.42% | -59.65% |
| Hyloris HYL | 177.52M Mid-cap | -3.77% | -4.38% | 4.44% | -4.38% | -4.38% | 6.62% | -52.19% | -40.00% |
Ownership & Short Interest
Insider Ownership
5.13%
Institutional Ownership
66.03%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
49K
Average 90-Day Volume
57K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is FAGR's 52-week high and low?
- In the last 52 weeks, Fagron NV reached a high of €23.50 (on July 31, 2025) and a low of €15.14 (on December 23, 2024).
- What is the market cap and P/E ratio for FAGR?
- Curious about Fagron NV's size and valuation? Its market capitalization stands at 1.46B. When it comes to valuation, the P/E ratio (trailing twelve months) is 17.08, and the forward P/E (looking ahead) is 15.14.
- Does FAGR pay dividends? If so, what's the yield?
- Yes, Fagron NV is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.60%, and the company has paid an average of €0.30 per share annually over the past 3 years.
- Who are Fagron NV's main competitors or similar companies to consider before investing?
When looking at Fagron NV, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Argenx SE
ARGX39.22B Healthcare Biotechnology 28.30% 73.61% UCB S.A
UCB39.10B Healthcare Biotechnology 25.08% 193.06% Ion Beam
IBAB333.57M Healthcare Medical Devices -18.34% -13.75% Onward Medical N.V
ONWD245.24M Healthcare Biotechnology 5.11% -16.42% Hyloris
HYL177.52M Healthcare Biotechnology 6.62% -52.19% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Fagron NV? (e.g., ROE, Debt/Equity)
- To get a sense of Fagron NV's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.53%, the Debt to Equity ratio from the most recent quarter is 80.02, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for FAGR?
- Looking at Fagron NV's growth, its revenue over the trailing twelve months (TTM) was €919M. Compared to the same quarter last year (YoY), quarterly revenue grew by 10.90%, and quarterly earnings saw a YoY growth of 12.70%.
- How much of FAGR stock is held by insiders and institutions?
- Wondering who owns Fagron NV stock? Company insiders (like executives and directors) hold about 5.13% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 66.03%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.